Antibody-Drug Conjugates and Immunotoxins
From Pre-Clinical Development to Therapeutic Applications
(Sprache: Englisch)
This volume collets leading research on antibody-drug conjugates and immunotoxins. It examines all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Voraussichtlich lieferbar in 3 Tag(en)
versandkostenfrei
Buch (Kartoniert)
Fr. 177.00
inkl. MwSt.
- Kreditkarte, Paypal, Rechnungskauf
- 30 Tage Widerrufsrecht
Produktdetails
Produktinformationen zu „Antibody-Drug Conjugates and Immunotoxins “
This volume collets leading research on antibody-drug conjugates and immunotoxins. It examines all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Klappentext zu „Antibody-Drug Conjugates and Immunotoxins “
This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Inhaltsverzeichnis zu „Antibody-Drug Conjugates and Immunotoxins “
Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins.- Antibody-Drug Conjugate Development.- Components of ADC Development: Assay Methodologies and Challenges.- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates.- Predictive Biomarkers for Antibody-Drug Conjugates.- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates.- Linker Technology and Impact of Linker Design on ADC Properties.- Antibody-drug conjugates for the treatment of B-cell malignancies.- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies.- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies.- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer.- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE).- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer.- EphA2 Immunoconjugate.- Anti-PSMA Antibody-Drug Conjugates.- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine.- Studies on the Metabolism of Antibody-Drug Conjugates.- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu.- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors.- Index.
Bibliographische Angaben
- 2015, 2013, X, 378 Seiten, Masse: 15,5 x 23,5 cm, Kartoniert (TB), Englisch
- Herausgegeben: Gail Lewis Phillips
- Verlag: Springer, Berlin
- ISBN-10: 1489997008
- ISBN-13: 9781489997005
Sprache:
Englisch
Kommentar zu "Antibody-Drug Conjugates and Immunotoxins"
0 Gebrauchte Artikel zu „Antibody-Drug Conjugates and Immunotoxins“
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Antibody-Drug Conjugates and Immunotoxins".
Kommentar verfassen